Stockreport

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors =3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study po [Read more]